Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 989,708 | 766,208 | 874,565 | 776,133 | 825,410 |
| Cost of Goods | 202,795 | 194,999 | 275,709 | 140,085 | 150,090 |
| Gross Profit | 786,913 | 571,209 | 598,856 | 636,048 | 675,320 |
| Operating Expenses | 676,788 | 442,568 | 644,175 | 682,825 | 398,523 |
| Operating Income | 110,920 | 129,640 | -44,610 | -46,692 | 276,887 |
| Interest Expense | 63,295 | 14,958 | 2,778 | 2,579 | 2,679 |
| Other Income | 13,759 | 26,521 | 20,235 | 22,947 | 23,660 |
| Pre-tax Income | 61,384 | 141,203 | -27,153 | -26,324 | 297,868 |
| Income Tax | 16,622 | 35,676 | 19,420 | 4,420 | 57,336 |
| Net Income Continuous | 44,762 | 105,527 | -46,573 | -30,744 | 240,532 |
| Net Income | $44,762 | $105,527 | $-46,573 | $-30,744 | $240,532 |
| EPS Basic Total Ops | 0.23 | 0.55 | -0.24 | -0.16 | 1.25 |
| EPS Basic Continuous Ops | 0.23 | 0.55 | -0.25 | -0.16 | 1.25 |
| EPS Diluted Total Ops | 0.23 | 0.54 | -0.22 | -0.16 | 1.23 |
| EPS Diluted Continuous Ops | 0.23 | 0.53 | -0.24 | -0.16 | 1.22 |
| EPS Diluted Before Non-Recurring Items | 0.90 | 0.58 | 0.28 | -0.08 | 1.25 |
| EBITDA(a) | $209,013 | $145,596 | $-25,278 | $-31,900 | $296,812 |